{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:59:49Z","timestamp":1790362789674,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020480","name":"CSL Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interleukin-6 (IL-6) is a key pleiotropic cytokine implicated in kidney injury; however, the therapeutic potential of IL-6 blockade against acute ischemia\u2013reperfusion injury (IRI) remains uncertain, with previous murine studies yielding conflicting results. This study investigated the protective effects of the high-affinity chimeric anti-IL-6 monoclonal antibody, cALD518-P18, in a non-transplant mouse model of warm renal IRI (22\u00a0min ischemia, 24\u00a0h reperfusion). Male C57BL\/6 mice received a single 40\u00a0mg\/kg dose of cALD518-P18 or an isotype control, administered either intraperitoneally 30\u00a0min before ischemia or intravenously immediately after ischemia. At 24\u00a0h, control mice exhibited significant kidney dysfunction (serum creatinine, urea), injury, and inflammation, consistent with elevated pro-inflammatory IL-6 trans-signalling (soluble IL-6R (sIL-6R) and tubular STAT3 phosphorylation (pSTAT3)). Treatment with cALD518-P18, in both regimens, significantly protected the kidneys from IRI, demonstrating improved renal function and reduced tissue damage. The antibody attenuated inflammation, endothelial activation and pSTAT3 signalling, significantly downregulating gene expression of the acute tubular stress marker NGAL. These findings confirm the pathogenic role of IL-6 and highlight its early blockade with cALD518-P18 as a promising therapeutic strategy to improve outcomes in acute kidney injury and transplantation.<\/jats:p>","DOI":"10.1038\/s41598-026-54952-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:46:09Z","timestamp":1779889569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The anti-interleukin-6 antibody ALD518-P18 mitigates murine kidney ischemia\u2013reperfusion injury"],"prefix":"10.1038","volume":"16","author":[{"given":"Anjan K.","family":"Bongoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Biondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn J.","family":"Salvaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nella","family":"Fisicaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenella","family":"Muntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Baz","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"54952_CR1","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4049\/jimmunol.181.3.2189","volume":"181","author":"CA Fielding","year":"2008","unstructured":"Fielding, C. A. et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181(3), 2189\u20132195 (2008).","journal-title":"J. Immunol."},{"issue":"10","key":"54952_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: Past, present and future prospects. Nat. Rev. Immunol. 23(10), 666\u2013681 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"54952_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502299","volume":"15","author":"EO Gubernatorova","year":"2024","unstructured":"Gubernatorova, E. O. et al. Targeting inerleukin-6 for renoprotection. Front. Immunol. 15, 1502299 (2024).","journal-title":"Front. Immunol."},{"key":"54952_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241283340","volume":"16","author":"PC Taylor","year":"2024","unstructured":"Taylor, P. C. et al. What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?. Ther. Adv. Musculoskelet. Dis. 16, 1759720X241283340 (2024).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"5","key":"54952_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/TP.0000000000004822","volume":"108","author":"M Berger","year":"2024","unstructured":"Berger, M. et al. Chronic active antibody-mediated rejection: Opportunity to determine the role of interleukin-6 blockade. Transplantation 108(5), 1109\u20131114 (2024).","journal-title":"Transplantation"},{"key":"54952_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084332","author":"F Lasorsa","year":"2024","unstructured":"Lasorsa, F. et al. Ischemia-reperfusion injury in kidney transplantation: Mechanisms and potential therapeutic targets. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25084332 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"54952_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1681\/ASN.2007070744","volume":"19","author":"Y Nechemia-Arbely","year":"2008","unstructured":"Nechemia-Arbely, Y. et al. IL-6\/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19(6), 1106\u20131115 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7090","key":"54952_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090), 235\u2013238 (2006).","journal-title":"Nature"},{"issue":"1","key":"54952_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1084\/jem.20081571","volume":"206","author":"O Dienz","year":"2009","unstructured":"Dienz, O. et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J. Exp. Med. 206(1), 69\u201378 (2009).","journal-title":"J. Exp. Med."},{"issue":"1","key":"54952_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), 40\u201350 (2014).","journal-title":"Immunity"},{"issue":"11","key":"54952_CR11","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1681\/ASN.2003090757","volume":"16","author":"ML Kielar","year":"2005","unstructured":"Kielar, M. L. et al. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol. 16(11), 3315\u20133325 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"54952_CR12","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1124\/jpet.104.078659","volume":"312","author":"NS Patel","year":"2005","unstructured":"Patel, N. S. et al. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia\/reperfusion. J. Pharmacol. Exp. Ther. 312(3), 1170\u20131178 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"54952_CR13","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/j.1600-6143.2009.02675.x","volume":"9","author":"DK de Vries","year":"2009","unstructured":"de Vries, D. K. et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am. J. Transplant. 9(7), 1574\u20131584 (2009).","journal-title":"Am. J. Transplant."},{"key":"54952_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.605675","volume":"8","author":"M Zuaiter","year":"2021","unstructured":"Zuaiter, M., Axelrod, J. H., Pizov, G. & Gofrit, O. N. Hyper-Interleukin-6 protects against renal ischemic-reperfusion injury-A mouse model. Front. Surg. 8, 605675 (2021).","journal-title":"Front. Surg."},{"issue":"12","key":"54952_CR15","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.4049\/jimmunol.1601943","volume":"198","author":"AK Bongoni","year":"2017","unstructured":"Bongoni, A. K. et al. Overexpression of human CD55 and CD59 or treatment with human CD55 protects against renal ischemia-reperfusion injury in mice. J. Immunol. 198(12), 4837\u20134845 (2017).","journal-title":"J. Immunol."},{"issue":"4","key":"54952_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000881","volume":"5","author":"AK Bongoni","year":"2019","unstructured":"Bongoni, A. K. et al. Complement-mediated damage to the glycocalyx plays a role in renal ischemia-reperfusion injury in mice. Transplant. Direct 5(4), e341 (2019).","journal-title":"Transplant. Direct"},{"issue":"5","key":"54952_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4049\/jimmunol.2000390","volume":"205","author":"JL McRae","year":"2020","unstructured":"McRae, J. L. et al. Blockade of the G-CSF receptor is protective in a mouse model of renal ischemia-reperfusion injury. J. Immunol. 205(5), 1433\u20131440 (2020).","journal-title":"J. Immunol."},{"issue":"1","key":"54952_CR18","doi-asserted-by":"publisher","first-page":"21873","DOI":"10.1038\/s41598-021-01423-y","volume":"11","author":"AK Bongoni","year":"2021","unstructured":"Bongoni, A. K. et al. A potent truncated form of human soluble CR1 is protective in a mouse model of renal ischemia-reperfusion injury. Sci. Rep. 11(1), 21873 (2021).","journal-title":"Sci. Rep."},{"issue":"16","key":"54952_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2424754122","volume":"122","author":"AK Bongoni","year":"2025","unstructured":"Bongoni, A. K. et al. Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 122(16), e2424754122 (2025).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"54952_CR20","unstructured":"Trial P. CSL Behring. Study to Evaluate Clazakizumab in Patients With End-Stage Kidney Disease on Dialysis (POSIBIL6). ClinicalTrials.gov identifier: NCT05485961. Updated December 22, 2025. Accessed February 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05485961."},{"issue":"3","key":"54952_CR21","first-page":"2019","volume":"19","author":"IWG Kim","year":"2019","unstructured":"Kim, I. W. G., Chai, N., Brennan, T., Klein, A. & Jordan, S. Neutralization of Interlukin-6 by ALD518-P18 (Murine Clazakizumab) Attenuates Donor Specific Antibody Responses in a Mouse Model of Allogeneic Sensitization: A Report of Dosage Finding Study. Am. J. Transplant. 19(3), 2019 (2019).","journal-title":"Am. J. Transplant."},{"issue":"8","key":"54952_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00467-015-3231-2","volume":"31","author":"K Maringer","year":"2016","unstructured":"Maringer, K. & Sims-Lucas, S. The multifaceted role of the renal microvasculature during acute kidney injury. Pediatr. Nephrol. 31(8), 1231\u20131240 (2016).","journal-title":"Pediatr. Nephrol."},{"issue":"4","key":"54952_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ajpath.2019.11.015","volume":"190","author":"MJ Butler","year":"2020","unstructured":"Butler, M. J., Down, C. J., Foster, R. R. & Satchell, S. C. The pathological relevance of increased endothelial glycocalyx permeability. Am. J. Pathol. 190(4), 742\u2013751 (2020).","journal-title":"Am. J. Pathol."},{"issue":"6","key":"54952_CR24","doi-asserted-by":"publisher","first-page":"F1151","DOI":"10.1152\/ajprenal.00034.2019","volume":"316","author":"J Pace","year":"2019","unstructured":"Pace, J., Paladugu, P., Das, B., He, J. C. & Mallipattu, S. K. Targeting STAT3 signaling in kidney disease. Am. J. Physiol. Renal Physiol. 316(6), F1151\u2013F1161 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"54952_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00405","volume":"8","author":"H Su","year":"2017","unstructured":"Su, H., Lei, C. T. & Zhang, C. Interleukin-6 signaling pathway and its role in kidney disease: An update. Front. Immunol. 8, 405 (2017).","journal-title":"Front. Immunol."},{"issue":"Suppl 4","key":"54952_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.17207","volume":"22","author":"SC Jordan","year":"2022","unstructured":"Jordan, S. C., Ammerman, N., Huang, E. & Vo, A. Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts. Am. J. Transplant. 22(Suppl 4), 28\u201337 (2022).","journal-title":"Am. J. Transplant."},{"issue":"5","key":"54952_CR27","doi-asserted-by":"publisher","first-page":"F553","DOI":"10.1152\/ajprenal.00595.2020","volume":"322","author":"JY Park","year":"2022","unstructured":"Park, J. Y. et al. Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis. Am. J. Physiol. Renal Physiol. 322(5), F553\u2013F572 (2022).","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"9","key":"54952_CR28","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi, J. et al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am. J. Transplant. 17(9), 2381\u20132389 (2017).","journal-title":"Am. J. Transplant."},{"issue":"1","key":"54952_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/ajt.16709","volume":"22","author":"T Jouve","year":"2022","unstructured":"Jouve, T. et al. Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates. Am. J. Transplant. 22(1), 71\u201384 (2022).","journal-title":"Am. J. Transplant."},{"issue":"7","key":"54952_CR30","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1074\/jbc.273.7.4135","volume":"273","author":"T Ichimura","year":"1998","unstructured":"Ichimura, T. et al. Kidney Injury Molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273(7), 4135\u20134142 (1998).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"54952_CR31","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00291.2005","volume":"290","author":"VS Vaidya","year":"2006","unstructured":"Vaidya, V. S., Ramirez, V., Ichimura, T., Bobadilla, N. A. & Bonventre, J. V. Urinary Kidney Injury Molecule-1: A sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. 290(2), F517\u2013F529 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"54952_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/00365510802145059","volume":"241","author":"JV Bonventre","year":"2008","unstructured":"Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A specific and sensitive biomarker of kidney injury. Scand. J. Clin. Lab. Invest. Suppl. 241, 78\u201383 (2008).","journal-title":"Scand. J. Clin. Lab. Invest. Suppl."},{"issue":"9466","key":"54952_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(05)74811-X","volume":"365","author":"J Mishra","year":"2005","unstructured":"Mishra, J. et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365(9466), 1231\u20131238 (2005).","journal-title":"Lancet"},{"issue":"2","key":"54952_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1681\/ASN.2006080882","volume":"18","author":"KM Schmidt-Ott","year":"2007","unstructured":"Schmidt-Ott, K. M. et al. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 18(2), 407\u2013413 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"54952_CR35","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/aas.14100","volume":"66","author":"S Mo","year":"2022","unstructured":"Mo, S., Bjelland, T. W., Nilsen, T. I. L. & Klepstad, P. Acute kidney injury in intensive care patients: Incidence, time course, and risk factors. Acta Anaesthesiol. Scand. 66(8), 961\u2013968 (2022).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"54952_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00153","volume":"10","author":"Y Dong","year":"2019","unstructured":"Dong, Y. et al. Ischemic duration and frequency determines AKI-to-CKD progression monitored by dynamic changes of tubular biomarkers in IRI mice. Front. Physiol. 10, 153 (2019).","journal-title":"Front. Physiol."},{"issue":"9","key":"54952_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf246","volume":"18","author":"V D'Ambrosio","year":"2025","unstructured":"D\u2019Ambrosio, V. et al. CRISPR and gene editing for kidney diseases: Where are we?. Clin. Kidney J. 18(9), sfaf246 (2025).","journal-title":"Clin. Kidney J."},{"key":"54952_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4609502","volume":"2017","author":"S Dube","year":"2017","unstructured":"Dube, S. et al. Endothelial STAT3 modulates protective mechanisms in a mouse ischemia-reperfusion model of acute kidney injury. J. Immunol. Res. 2017, 4609502 (2017).","journal-title":"J. Immunol. Res."},{"key":"54952_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147280","author":"N Martino","year":"2021","unstructured":"Martino, N. et al. Endothelial SOCS3 maintains homeostasis and promotes survival in endotoxemic mice. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.147280 (2021).","journal-title":"JCI Insight"},{"issue":"2","key":"54952_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/BCJ20240569","volume":"482","author":"A Pefanis","year":"2025","unstructured":"Pefanis, A. et al. Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury. Biochem. J. 482(2), 73\u201386 (2025).","journal-title":"Biochem. J."},{"key":"54952_CR41","unstructured":"Keppel, G. & Wickens, T. D. Design and Analysis: A Researcher\u2019s Handbook (4th ed.). Pearson Prentice Hall 2004; ISBN: 0135159415, 9780135159415"},{"issue":"7139","key":"54952_CR42","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","volume":"316","author":"TV Perneger","year":"1998","unstructured":"Perneger, T. V. What\u2019s wrong with Bonferroni adjustments. BMJ 316(7139), 1236\u20131238 (1998).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54952-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:43:35Z","timestamp":1785973415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54952-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54952"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54952-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B., T.R., and A.B.M. are CSL shareholders. Other authors have no financial conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"24286"}}